PriceTargets.com logo

FibroBiologics - FBLG Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.00
  • Forecasted Upside: 477.78%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$2.25 As of 12/20/2024 06:31 PM ET
▲ +0.22 (10.84%)

This chart shows the closing price for FBLG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New FibroBiologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FBLG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FBLG

Analyst Price Target is $13.00
▲ +477.78% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for FibroBiologics in the last 3 months. The average price target is $13.00, with a high forecast of $16.00 and a low forecast of $12.00. The average price target represents a 477.78% upside from the last price of $2.25.

This chart shows the closing price for FBLG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in FibroBiologics. This rating has held steady since October 2024, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2024Rodman & RenshawInitiated CoverageBuy$12.00
11/20/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
10/30/2024HC WainwrightInitiated CoverageBuy$12.00
9/24/2024Maxim GroupInitiated CoverageBuy$12.00
9/4/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

FibroBiologics logo
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
Read More

Today's Range

Now: $2.25
Low: $2.02
High: $2.29

50 Day Range

MA: $2.74
Low: $2.01
High: $3.72

52 Week Range

Now: $2.25
Low: $1.08
High: $55.00

Volume

224,053 shs

Average Volume

245,662 shs

Market Capitalization

$77.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of FibroBiologics?

The following Wall Street research analysts have issued reports on FibroBiologics in the last twelve months: D. Boral Capital, EF Hutton Acquisition Co. I, HC Wainwright, Maxim Group, and Rodman & Renshaw.
View the latest analyst ratings for FBLG.

What is the current price target for FibroBiologics?

0 Wall Street analysts have set twelve-month price targets for FibroBiologics in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 477.8%. D. Boral Capital has the highest price target set, predicting FBLG will reach $16.00 in the next twelve months. Rodman & Renshaw has the lowest price target set, forecasting a price of $12.00 for FibroBiologics in the next year.
View the latest price targets for FBLG.

What is the current consensus analyst rating for FibroBiologics?

FibroBiologics currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FBLG will outperform the market and that investors should add to their positions of FibroBiologics.
View the latest ratings for FBLG.

What other companies compete with FibroBiologics?

Other companies that are similar to FibroBiologics include Immutep, Larimar Therapeutics, COMPASS Pathways, AC Immune and Benitec Biopharma. Learn More about companies similar to FibroBiologics.

How do I contact FibroBiologics' investor relations team?

FibroBiologics' physical mailing address is 455 East Medical Center Boulevard, Suite 300, Houston, TX 77598, United States. The company's listed phone number is 281-671-5150 and its investor relations email address is [email protected]. The official website for FibroBiologics is www.fibrobiologics.com. Learn More about contacing FibroBiologics investor relations.